5+ day, 1+ hour ago   (190+ words) Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company…...

5+ day, 4+ hour ago   (83+ words) "STIMULAN® gained MDR certification earlier this year and is the only calcium matrix that can be mixed with a combination of antibiotics, resolve infection and reduce the need for secondary surgery.” Details of Biocomposites’ symposium at the EBJIS-MSIS Conference are…...

5+ day, 16+ hour ago   (847+ words) The Manila Times - Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes - Preclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and…...

6+ day, 6+ hour ago   (302+ words) GRWD0715, a first-in-class oral ERAP1 inhibitor to treat CD8+ T cell-mediated autoimmunity, has now been dosed in participants with axSpA after the completion of the SAD portion of its Phase 1/2 study (EAST-1) in healthy volunteers, demonstrating dose-proportional PK, clear evidence of ERAP1 target engagement,…...

6+ day, 10+ hour ago   (160+ words) HORIEN Biotech IPO in Taiwan Thai FDA Class 4 Approved Portfolio 2. "Horien" Collagen Matrix A highly biocompatible collagen plug and sheet designed for rapid fluid absorption, local clot stabilization, and superior wound coverage across surgical and dental interventions. 3. "Horien" Extracellular Membrane…...

6+ day, 16+ hour ago   (135+ words) BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term safety and effectiveness of the Genio therapy in real-world clinical practice First implant performed by Rolando Molina, MD,…...